BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Long-term Pre-dialysis Extension in Europe and Asia Pacific
Phase 2
Completed
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- Drug: Molidustat (BAY85-3934)Biological: Darbepoetin
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 166
- Registration Number
- NCT02055482
- Locations
- 🇹🇷
Baskent University Medical Faculty, Ankara, Turkey
🇹🇷Ankara Univ. Medical Faculty, Ankara, Turkey
🇹🇷Sifa University Medical Faculty, Izmir, Turkey
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Phase 3
Withdrawn
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Bayer
- Registration Number
- NCT02047019
- Locations
- 🇮🇹
AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy
🇮🇹IRCCS Ist Neurologico Mediterraneo, Isernia, Molise, Italy
🇮🇹Fondazione Università G.D'Annunzio, Chieti, Abruzzo, Italy
Japanese BAY1000394 Monotherapy Phase I Study
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY1000394 (2.5mg)Drug: BAY1000394 (5mg)
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT02047890
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Phase 3
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Matching placebo (normal saline)Drug: Radium-223 dichloride (Xofigo, BAY88-8223)Drug: AbirateroneDrug: Prednisone/Prednisolone
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 806
- Registration Number
- NCT02043678
Safety and Effectiveness of Regorafenib
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1034
- Registration Number
- NCT02042144
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
Completed
- Conditions
- Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 385
- Registration Number
- NCT02040220
Multiple Dose Study in Heart Failure of BAY 1067197
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: BAY1067197 (10 mg)Drug: BAY1067197Drug: PlaceboDrug: Placebo (10 mg)
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31
- Registration Number
- NCT02040233
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT02034552
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: lloprost(Ventavis,BAYQ6252, 20 µg/mL)Drug: lloprost(Ventavis,BAYQ6252, 10 µg/mL)
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT02032836
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 391
- Registration Number
- NCT02023697
- Locations
- 🇧🇷
Instituto do Câncer do Estado de São Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
© Copyright 2025. All Rights Reserved by MedPath